

Analytical Assurance Statement

Despite falling in scope of a de minimis assessment (DMA), an impact assessment (IA) has been undertaken in line to publish. The Analytical Assurance rating is **medium**.

There is data available on the number of ENG1 assessments undertaken each year and the proportion undertaken overseas, enabling a UK estimate to be made. There is also information on the costs of comparable medical assessments which are used to inform cost estimates. This information is used to produce an estimate of the additional costs to the seafarers and firms who have ENG1s, and therefore the equivalent benefit to the approved doctors.

There are some **medium uncertainties** around the analysis. There is no evidence on the proportion of seafarers who pay for their own medicals, or data on where the companies are from or where the seafarers are from, which means that it has not been possible to estimate the net impact of UK business by overseas firms or individuals paying UK doctors for the ENG1 assessment. It is also uncertain whether the prices will go up (possibly to cover doctors' costs) or down (as a result of price competition) as a result of the policy change. Therefore, we have assumed that the transfers will be between businesses and will be net of zero, which is reasonable due to the scale of the intervention. No transition costs have been identified.

Further evidence will be sought through the consultation process to assess the validity of assumptions made in the IA. The analysis is proportionate to the scale of the intervention. Although the AA is thought to be medium, **the risk of challenge to the analysis** is also expected at this stage to be **low**.